Back to results
US 2025/0082684 A1Published application
Recombinant Cell Line Expressing Membrane Proteins and Vesicles Prepared Therefrom
OwnerJan Lötvall, Kyong-su Park +1inventors
InventorsJan Lötvall, Kyong-su Park, Cecilia Lasser
Life of this patent
Estimating the term…
Abstract
The present disclosure provides vesicles prepared from a mammalian cell line genetically modified to overexpress one or more membrane proteins as provided in the disclosure. The genetically modified cells are also provided. The vesicles find use in methods for reducing inflammatory response in a subject in need thereof.
Claims36
A composition comprising:
- vesicles prepared from a mammalian cell line genetically modified to overexpress a membrane protein selected from the group consisting of:
- bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1 (NDST1), ferroptosis suppressor protein 1 (AIFM2), cysteine-rich and transmembrane domain-containing protein 1 (CYSTM1), cadherin-6 (CDH6), solute carrier family 22 member 18 (SLC22A18), promethin (TMEM159), receptor-type tyrosine-protein phosphatase kappa (PTPRK), prolyl endopeptidase FAP (FAP), phospholipid-transporting ATPase ID (ATP8B2), ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 (BST1), reticulon-2 (RTN2), ras-related protein Rap-1A (RAP1A), basigin (BSG), aldehyde dehydrogenase family 3 member B1 (ALDH3B1), calsyntenin-1 (CLSTN1), small VCP/p97-interacting protein (SVIP), GTP-binding protein Rheb (RHEB), lysophosphatidic acid receptor 1 (LPAR1), prolow-density lipoprotein receptor-related protein 1 (LRP1), receptor-type tyrosine-protein phosphatase F (PTPRF), raftlin (RFTN1), guanine nucleotide-binding protein G (q) subunit alpha (GNAQ), guanine nucleotide-binding protein subunit alpha-11 (GNA11), integrin alpha-8 (ITGA8), roundabout homolog 1 (ROBO1), ADP-ribosylation factor 6 (ARF6), ephrin type-B receptor 2 (EPHB2), transforming protein RhoA (RHOA), proto-oncogene tyrosine-protein kinase Src (SRC), synaptobrevin homolog YKT6 (YKT6), Ras-related protein Rab-23 (RAB23), vascular cell adhesion protein 1 (VCAM1), lymphocyte function-associated antigen 3 (CD58), guanine nucleotide-binding protein G (I)/G(S)/G (O) subunit gamma-12 (GNG12), 2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNP), receptor-type tyrosine-protein phosphatase eta (PTPRJ), guanine nucleotide-binding protein G(s) subunit alpha isoforms short (GNAS), ADP-ribosylation factor 5 (ARF5), mitochondrial calcium uniporter regulator 1 (MCUR1), nuclear mitotic apparatus protein 1 (NUMA1), protein/nucleic acid deglycase DJ-1 (PARK7), V-type immunoglobulin domain-containing suppressor of T-cell activation (VISTA), CD276, Cell surface glycoprotein MUC18 (MCAM), and Phosphatidylserine synthase 2 (PTDSS2);
- and
- a pharmaceutically acceptable carrier,
- wherein the vesicles when administered to a subject reduces the levels of at least one proinflammatory cytokine in the subject.
2 more elements
A mammalian cell, wherein the mammalian cell is genetically modified to overexpress a membrane protein selected from the group consisting of:
- bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1, ferroptosis suppressor protein 1, cysteine-rich and transmembrane domain-containing protein, cadherin-6, solute carrier family 22 member 18, promethin, receptor-type tyrosine-protein phosphatase kappa, prolyl endopeptidase FAP, phospholipid-transporting ATPase ID, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2, reticulon-2, ras-related protein Rap-1A, basigin, aldehyde dehydrogenase family 3 member B1, calsyntenin-1, small VCP/p97-interacting protein, GTP-binding protein Rheb, lysophosphatidic acid receptor 1, prolow-density lipoprotein receptor-related protein 1, receptor-type tyrosine-protein phosphatase F, raftlin, guanine nucleotide-binding protein G (q) subunit alpha, guanine nucleotide-binding protein subunit alpha-11, integrin alpha-8, roundabout homolog 1, ADP-ribosylation factor 6, ephrin type-B receptor 2, transforming protein RhoA, proto-oncogene tyrosine-protein kinase Src, synaptobrevin homolog YKT6, Ras-related protein Rab-23, vascular cell adhesion protein 1, lymphocyte function-associated antigen 3, guanine nucleotide-binding protein G (I)/G(S)/G (O) subunit gamma-12, 2′,3′-cyclic-nucleotide 3′-phosphodiesterase, receptor-type tyrosine-protein phosphatase eta, guanine nucleotide-binding protein G(s) subunit alpha isoforms short, ADP-ribosylation factor 5, mitochondrial calcium uniporter regulator 1, nuclear mitotic apparatus protein 1, protein/nucleic acid deglycase DJ-1, V-type immunoglobulin domain-containing suppressor of T-cell activation, CD276, MCAM and Phosphatidylserine synthase 2.
Dependencies are inferred from the claim text.